.Pharmacolibrary.Drugs.ATC.A.A16AB23 .Pharmacolibrary.Drugs.ATC.A.A16AB23| name: | CipaglucosidaseAlfa |
| ATC code: | A16AB23 | route: | intravenous |
| n-compartments | 1 |
Cipaglucosidase alfa is a recombinant human acid alpha-glucosidase (GAA) enzyme replacement therapy (ERT) indicated for the treatment of Pompe disease, a lysosomal storage disorder caused by GAA deficiency. It is currently approved for use in combination with miglustat.
Pharmacokinetic parameters are estimated for adults with late-onset Pompe disease based on typical dosing and available regulatory documents. No peer-reviewed publications or DOIs report pharmacokinetic parameters for cipaglucosidase alfa.